Pentoxifylline for Acute Alcoholic Hepatitis (AAH)

Phase 1TerminatedNCT00205049

University of Wisconsin, Madison4 enrolled

Overview

The goal of this study is to demonstrate the effectiveness of pentoxifylline compared to placebo in AAH while studying putative mechanisms that are plausible and testable. The main hypothesis is that pentoxifylline reduces the 90-day mortality of AAH.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Hepatitis, Alcoholic

Interventions

pentoxifyllineDRUG

daily dosing

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Inpatient with acute alcoholic hepatitis * Model for End-Stage Liver Disease (MELD) of 15 or greater * Recent alcohol abuse Exclusion Criteria: * Recent infection * Other life threatening disease * Severe coagulopathy * Another non-alcoholic cause of liver disease

Outcomes

Primary Outcomes

Survival at 28 Days

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.